Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Camurus AB (0RD1) Price & Analysis

0RD1 Stock Chart & Stats

SEK 674.50SEK 3.50(0.52%)
At close: 4:00 PM EDT
SEK 600SEK 6503 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
SEK 669.50 - SEK 674.50
52-Week Range
SEK 433.00 - SEK 707.50
Previous Close
SEK 671.00
Volume
231
Average Volume (3M)
14.23K
Market Cap
SEK 40.76B
Enterprise Value
SEK 29.70B
Total Cash (Recent Filing)
SEK 4.07B
Total Debt (Recent Filing)
SEK 108.40M
Price to Earnings (P/E)
59.1
Beta
0.79
Next Earnings
Nov 05, 2026
EPS Estimate
3.71
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Growth

Growth is supported by expanding patient treatment and stronger royalty flows, not just a single product shipment. Buvidal’s increasing adoption and Brixadi’s U.S. momentum can reinforce recurring revenue, improve commercial scale, and support continued expansion over the next several quarters.

Profitability And Balance Sheet

Exceptional margins indicate substantial economic value from Camurus’s products and technology, while very low leverage limits financial risk. The combination of profitability and a conservative balance sheet gives management flexibility to fund launches, research, and regulatory work without relying heavily on external financing.

Pipeline And Technology Validation

Multiple clinical and partnership catalysts diversify the company beyond its established opioid-dependence products. Progress in long-acting formulations and Lilly’s expanded collaboration provide evidence that FluidCrystal has broader commercial potential, supporting future product and royalty opportunities.

Bears Say

U.S. Regulatory Timing

The Complete Response Letter delays the U.S. approval pathway for CAM2029 and creates dependence on remediation acceptance and a likely follow-up inspection. Even though the issue was not linked to efficacy or safety, uncertain timing can defer commercialization, revenue contribution, and return on development investment.

Cash-flow Momentum And Investment Spending

Absolute cash generation remains healthy, but declining free cash flow and higher working-capital needs reduce near-term conversion of earnings into available cash. Planned commercial and R&D spending may support growth, yet it also increases execution demands and can temporarily constrain financial flexibility.

Australian Capacity Constraints

Patient and clinic capacity constraints can limit prescription growth even when underlying demand for long-acting treatment is attractive. This makes the Australian contribution less predictable over the next several months and may delay the benefit of potential patient transfers following a competitor’s withdrawal.

Camurus AB News

0RD1 FAQ

What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest share price was kr 433.00 and its highest was kr 707.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr 40.76B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Jul 15, 2026. The company reported kr 4.065 earnings per share for the quarter, beating the consensus estimate of kr 3.227 by kr 0.838.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB pays a Notavailable dividend of kr 0.285 which represents an annual dividend yield of ―. See more information on Camurus AB dividends here
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 3.71.
How many shares outstanding does Camurus AB have?
Camurus AB has 60,559,185 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr 4.065 in its last earnings report, beating expectations of kr 3.227. Following the earnings report the stock price went up 14.639%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in GB:0RD1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology